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1912 INTEGRATIVE PATHWAY ANALYSIS OF METABOLIC SIGNATURE IN BLADDER CANCER(Kyoto Encyclopedia of Genes and Genomes) Database we identified a total of 174 genes that correlated with
the altered metabolic pathways involved. By integrating these genes with the transcriptomic data from
the corresponding TCGA data set we identified a metabolic signature consisting of 30 genes. The signature
was significant in its prediction of survival in 95 patients with a low signature score vs 282 with a high
signature score (p ¼ 0.0458).
Conclusions: Targeted mass spectrometry of bladder cancer is highly sensitive for detecting metabolic
alterations. Applying transcriptome data allows for integration into larger data sets and identification of
relevant metabolic pathways in bladder cancer progression.
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metabolic networks and pathwaysTable 1. Clinical characteristics of 60 patients
No. Pts (%)
Pathological stage:
Ta 1 (2)
T1 1 (2)
T2 12 (19)
T3 23 (37)
T4 9 (14)
Normal 14 (22)
Grade:*
High 44 (96)
Missing 2 (4)
Lymph node metastasis:
Present 21 (45)
Absent 25 (53)
Neoadjuvant chemotherapy:
Present 6 (13)
Absent 40 (85)
*No low grade BCa.UROTHELIAL BCa is the second most prevalent uro-
logical malignancy and the fourth most common
cause of cancer in men in the United States.1
Because most patients present with nonmuscle
invasive BCa at the time of diagnosis, this cancer
can be managed by bladder sparing approaches.
Conversely most patients who present with gross
hematuria will have muscle invasive disease. The
biological processes that are associated with tumor
progression are poorly understood.
While radical cystectomy offers excellent survival
rates for organ confined disease, the outcome is
inferior in patients with advanced disease as well
as those who undergo delayed cystectomy for non-
muscle invasive BCa.2 A significant limitation in
the management of advanced disease is the inability
to predict the patients who are most likely to
respond to systemic chemotherapy. A wide spec-
trum of urinary and molecular markers has been
evaluated but none have been shown to predict the
natural history of BCa in the clinical setting.3
Physicians currently rely predominantly on histo-
logical grade and primary tumor stage from initial
bladder tumor resection as well as cross-sectional
imaging to assess the risk of disease progression
in individual patients.
Unlike other tumors BCa is closely linked to
environmental carcinogens, including tobacco,
polyaromatic hydrocarbons, aniline, benzidine,
naphthylamine and multiple other compounds.4 Our
group has previously performed unbiased meta-
bolic profiling of bladder derived tissues and was
able to report the accumulation of aromatic com-
pounds and xenobiotic compounds in tumors.5 In
this context elevated levels of SAM (S-adenosyl
methionine) were indicative of increased methyl-
ation potential in these tumors. Notably the latter
contributes to the decreased expression of enzymes
in the cytochrome driven phase I metabolic path-
way, which could potentially lead to alterations in
precarcinogen metabolism in bladder tissues.
A recently published, comprehensive molecular
analysis of urothelial BCa from TCGA (http://cancergenome.nih.gov/) has provided us with novel
insights into molecular subgroups and potential
targets for targeted therapies.6 We have asked the
question of whether we could define a metabolic
gene signature associated with progression and
survival by integrating metabolomic pathway anal-
ysis based on a validated targeted mass spectrom-
etry platform with TCGA transcriptome profiles.
Our report provides insight into metabolic path-
ways that are potentially associated with tumori-
genesis and tumor progression.PATIENTS AND METHODS
Bladder Tumor Metabolomic Profiling
A total of 60 pathologically verified tissues, including
benign adjacent tissue from 14 patients and BCa from 46
(table 1), were obtained from the tumor banks of the
participating institutions (Baylor College of Medicine,
University of Texas Southwestern Medical Center and
University of Witten-Herdecke). All samples were de-
identified and included in study under an institutional
review board approved protocol (H-35808).
Flash frozen, macrodissected tumor samples as well
as adjacent noncancerous tissues were reviewed by a
Figure 1. Overview of strategy used to profile and characterize BCa metabolome
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muscle invasive bladder tumors and 21 patients were
found to have lymph node metastasis at the time of tissue
collection. Tissue was retrieved at transurethral tumor
resection or cystectomy. All patients ultimately under-
went radical cystectomy and pathological tumor stage was
available for all. Six of the 46 patients received neo-
adjuvant chemotherapy.
Tissues were analyzed by liquid chromatography-mass
spectrometry. The metabolome was separated using
reverse phase and aqueous normal phase chromatog-
raphy, and examined by mass spectrometry using posi-
tive and negative electrospray ionization. The mass
spectrometer was used to examine 145 metabolites by
single reaction monitoring. Figure 1 shows a schematicoverview of the metabolomic profiling and the associated
data analysis strategy used in this study. The chro-
matographic separation of metabolites and analysis by
mass spectrometry were monitored for drifts using in-
ternal standards and biological replicates of pooled
extract of mouse liver and were found to be highly
reproducible.
Liquid Chromatography/Mass Spectrometry
Samples were injected and analyzed using the 6490
Triple Quadrupole mass spectrometer coupled to a high
performance liquid chromatography system (Agilent)
via single reaction monitoring of 145 endogenous water
soluble metabolites for steady-state analyses of samples.
The 145 compounds monitored were chosen due to
Table 2
Gene Log2_FC(tumor/benign)
XDH 4.28
TDO2 3.73
GAD1 2.88
CHIT1 2.86
DNMT3B 2.54
PYCR1 2.53
KMO 1.83
TYMP 1.52
PYCRL 1.45
SUV420H2 1.2
B4GALT3 1.14
LYPLA2 1.08
PLA2G15 1.08
DNMT1 1
NNMT 1.01
BST1 1.05
TARSL2 1.1
SETD7 1.12
GPD1 1.13
GPD1L 1.19
EXTL1 1.32
GATM 1.33
GAMT 1.43
ALDH7A1 1.64
DPYD 1.66
ALDH1B1 1.76
PLA2G4A 1.77
PIPOX 1.96
ALDH2 2.37
INMT 2.61
1914 INTEGRATIVE PATHWAY ANALYSIS OF METABOLIC SIGNATURE IN BLADDER CANCERinvolvement in central pathways important in a number
of malignancies. Source parameters were gas tempera-
ture 250C, gas flow 14 L per minute, nebulizer 20 psi,
sheath gas temperature 350C, sheath gas flow 12 L per
minute, capillary 3,000 V positive and 3,000 V nega-
tive, and nozzle voltage 1,500 V positive and 1,500 V
negative.
Approximately 8 to 11 data points were acquired per
detected metabolite. Samples were delivered to the mass
spectrometer via normal phase chromatography using a
4.6 mm inner diameter  10 cm XBridge HILIC Amide
Column or a Luna 3 m NH2 100 A˚ Column at 300 ml per
minute. Gradients were run starting from 85% buffer B
(high performance liquid chromatography grade acetoni-
trile or 0.1% formic acid in acetonitrile) to 35% B from 0 to
3.5 minutes and from 35% B to 2% B from 3.5 to 11.5 min-
utes with 2% B held from 11.5 to 16.5 minutes, 2% B to
85% B held from 16.5 to 17.5 minutes and 85% B held for
7 minutes to re-equilibrate the column. The peak area of
each metabolite was integrated using MassHunter
Workstation Software Quantitative Analysis, version
B.06.00 (Agilent).
Statistical Analysis
Metabolite levels were normalized relative to the me-
dian level of spiked internal standards (zeatin and
tryptophan 15 N2) separately for all 4 methods used.
Data were log2-transformed and median centered. For
every metabolite in the normalized data set the 2-
sample t-test was applied to compare expression levels
in BCa and adjacent benign tissues. Differential me-
tabolites were identified after adjusting p values for
multiple testing at a false discovery rate threshold of
15%. Hierarchical clustering of differential metabolites
was generated using the R statistical system (https://
www.r-project.org/).
Integration of Metabolomic and Transcriptomic
Data
We integrated the common metabolites with urothelial
BCa transcriptome data published by TCGA. Metabolites
were converted to KEGG Database (http://www.genome.
jp/kegg/kegg1.html) enzyme/gene IDs using an in-house
database. We determined the enrichment of pathways
and biological processes in this signature using the
collections compiled by the GO Database (http://
geneontology.org/page/go-database) and MSigDB (http://
software.broadinstitute.org/gsea/msigdb/). We performed
overrepresentation analysis of pathways based on the
hypergeometric distribution (p <0.05) of the biochemical
genes.
Next we obtained the transcriptome fingerprint
between matched normal and tumor tissues in TCGA
urothelial BCa data set (fold change exceeding twofold,
p <0.05). We generated an integrated metabolomics/
transcriptomics gene signature by intersecting the
mentioned gene sets. A total of 30 genes found to be
differential between BCa and matched adjacent benign
tissues in TCGA were also associated with metabolites
significantly altered between tumor and adjacent
matched benign tissues. This set of 30 genes and the
associated fold changes in TCGA data were termed theintegrated metabolomic/transcriptomic gene signature
(table 2).
Analysis of Integrated Tumor Progression Gene
Signature Prognosis Power
The significant association with survival of an integrated
metabolomic/transcriptomic gene signature was evalu-
ated in a gene expression data set corresponding to the
urothelial BCa patient cohort from TCGA working group,
for which clinical outcomes have been reported. For each
gene in the signature and for each specimen we calculated
the z-score for expression in the cohort as described pre-
viously.7 We then calculated the sum z-score for each
specimen. Specifically the z-scores of genes repressed
in the integrated signature were subtracted from the
z-scores of genes induced in the integrated signature,
resulting in a corresponding signature activity score for
each specimen. In each data set specimens were ranked
according to the integrated signature activity score and
the association with survival was evaluated by the log-
rank test between the bottom 25% and the top 75% of
the patients. Survival significance was assessed by the
survival package in R.
Generation of Focused Integrated Gene Signature
Associated with Prognosis in Multiple Cohorts
We analyzed the association of the integrated 30-gene
signature with survival in additional BCa cohorts,
including those reported by Kim et al (GSE13507)8 and
Lindgren et al (GSE32548).9 Using the exploratory
approach of partitioning samples based on multiple
thresholds (eg comparing the top 33% to the bottom 33%,
Figure 2. Metabolomic alteration in BCa and heat map shows 31 named differential metabolites in urothelial cancer relative to benign
samples. Columns represent individual tissue samples. Rows represent distinct metabolites. Yellows indicate metabolite elevation.
Greens indicate metabolite decrease relative to average level (Color Key).
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et al10 we determined that the 30-gene signature was
associated with progression in all 3 cohorts, although at
different thresholds.
To generate a robust signature with potential clinical
application we evaluated whether a subset of the 30 genes
could be associated with prognosis using the same
breakdown in all 3 cohorts. We first selected 13 genes
associated with survival in the same direction in all 3 data
sets regardless of the sample breakdown. By applying
combinatorial analysis we next determined a subset
signature associated with survival at the bottom 25%-
top 75% sample breakdown. This consisted of the
genes CHIT1, DNMT1, GPD1, PLA2G4A, TARSL2 and
SETD7.RESULTS
Bladder Cancer Metabolomic Profiling
We analyzed 60 bladder derived tissues, including
14 benign adjacent tissues and 46 BCa tissues, for
metabolomic profiles using liquid chromatography-
mass spectrometry. A total of 145 metabolites
were measured on the platform across the 60 tis-
sue samples. There was no difference in metabo-
lite levels in the tumor cohort with regard to
tumor stage or presence of metastatic disease.
However 31 of these metabolites were differen-
tially altered between tumor and benign samples
(fig. 2).
1916 INTEGRATIVE PATHWAY ANALYSIS OF METABOLIC SIGNATURE IN BLADDER CANCERFrom these data we were able to categorize all
differential metabolites into various subgroups
based on function and/or class. These classifications
included metabolites associated with tryptophan
metabolism (tryptophan, kynurenine and 3-
hydroxykynurenine), the methylation pathway
(SAH, SAM, S-ribosyl-homocysteine, methionine
and cystathionine), the glycine, serine and threo-
nine pathway (sarcosine, asparagine, homoserine
and threonine), the nicotinate and nicotinamide
pathway (NAD and nicotinamide), nucleotides/
purine metabolism (xanthine and thymine), acetyl
amino acids (acetyl lysine, UDP-acetyl-glucosamine,
acetyl-glutamine and acetyl butyric acid) and
other metabolites (valine, glycine-leucine, proline,
4-coumarate, tyrosine and 2-aminobutyraldehyde,
propionyl carnitine, and 4-aminobutyrate).
Robust Metabolic Changes between Adjacent
Normal and Tumor Tissues
To further obtain insights into altered biochemical
pathways we mapped the differential set of metabo-
lites to the correspondinggenes,whichwere thenused
to enrich for biochemical pathways. Pathway enrich-
ment analysis nominated 39 significantly enriched
biochemical pathways (p<0.05).Of thesepathways24
were highly interconnected and related to the syn-
thesis of amino acids, namely lysine, cysteine, methi-
onine, arginine, proline, tryptophan and alanine as
well as glycolysis, lipid metabolism and fatty acids
(fig. 3). Pathway network was visualized with Cyto-
scape software (http://www.cytoscape.org/).
Next we used TCGA to cull the list of differential
genes between urothelial carcinoma and benign tis-
sue. A total of 3,779 genes were found to be differen-
tial (fold change exceeding twofold, p <0.05). When
overlapped with the gene list corresponding to the
differential metabolites described, 30 genes were
obtained (table 2). These genes were significantly
altered between urothelial carcinoma and benign
tissue in TCGA, and they were also associated with
metabolites significantly altered between benign and
BCa tissues. This core set of 30 genes was examined
for its prognostic power in TCGA data set.
This integrated metabolomic/transcriptomic gene
signature was significantly associated with survival
in TCGA cohort of patients with urothelial cancer
(log-rank test p ¼ 0.0458, Cox proportional hazards
p ¼ 0.0360, fig. 4). Patients with a higher activity
score for the integrated signature showed a worse
prognosis. Using combinatorial analysis we identi-
fied a subset 6-gene signature associated with sur-
vival in additional cohorts, namely those of Kim8
and Lindgren9 et al, consisting of the genes CHIT1,
DNMT1, GPD1, PLA2G4A, TARSL2 and SETD7
(fig. 4, C and D).DISCUSSION
We report mass spectrometry based, metabolic
pathway analysis of urothelial cancer of the bladder.
We were able to identify commonly altered
biochemical pathways and determine a metabolite
derived gene signature that we found was predictive
of greater than 10-year survival in TCGA data set.
By integrating metabolomic pathway analysis based
on a validated targeted mass spectrometry platform
with TCGA transcriptome profiles we were able to
define a metabolic gene signature associated with
progression and survival.11 This allows for evalua-
tion of the biological role as well as the clinical
relevance of the signature.
The idea of coupling data from different aspects
of the same biological system, a term known as
integrative analysis, is not new.12e15 In several
recent studies this concept was applied to identify
gene function or gene-to-metabolite networks but to
our knowledge the current data set represents a
novel approach to BCa metabolomics.
The scope of our targeted mass spectrometry
based analysis involved 145 metabolites, including
amino acids, amino sugars, nucleotides, organic
acids and fatty acids. A total of 31 metabolites were
differentially enriched when comparing benign
bladder and bladder tumor samples. Enrichment
analysis highlighted multiple biological processes in
the enrichment grid with an emphasis on amino
acid metabolism, nucleotides, lipids and glycolysis
(fig. 4). This is coherent with the metabolic re-
quirements for cell proliferation proposed by Vander
Heiden et al.16
The Warburg effect is a phenomenon in cancer
cells in which they rapidly metabolize glucose to
lactate using cytosolic aerobic glycolysis rather than
the more efficient generation of adenosine triphos-
phate through mitochondrial oxidative phosphory-
lation. While we observed pathway alterations
associated with the Warburg effect (glycolysis and
pyruvate metabolism), our analysis did not show
specific metabolite changes, which are better evalu-
ated by flux analysis. On integrated pathway anal-
ysis we found a significant overlap with a previously
reported metabolic signature (supplementary figure,
http://jurology.com/),17 which is supportive of the
biological importance.5 This is in agreement with
reports indicating alterations in amino acid levels
and the potential association with tumor
development.
Up to 70% of dry cell weight consists of protein,
which directly correlates with a demand for protein
synthesis. While essential amino acids cannot be
synthesized in the cell, the flux profile of the amino
acids might be an indicator of protein synthesis
dynamics in cancer cells. A recent study revealed a
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Figure 3. A, enriched pathways and processes in metabolomic gene signature (hypergeometric distribution p <0.05). Differential set of
metabolites was mapped to corresponding genes, which were used to enrich for biochemical pathways. Red indicates pathways
associated with current metabolic signature. Green indicates pathways associated with previous metabolic signature.17 B, pathways
common to current and previous17 metabolic signatures. C, novel pathways from current metabolic signature.
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and cancer cell proliferation in cell line models.18
Metabolomics may be helpful to identify patterns
in amino acid metabolism that can be modified by
targeted drugs. A valuable example is the effect of
mTOR inhibitors on protein synthesis in cancer
cells.19A metabolomics approach captures the actual
real-time metabolism but single metabolites may
not be reflective of a pattern simply because the
metabolic state undergoes constant change. On
the contrary focusing on pathways rather than on
single metabolites appears to be more reflective of
important biological processes. The integration of
Figure 4. Survival analyses. A, in TCGA-BLCA (Bladder Urothelial Carcinoma) cohort for integrated metabolomics/transcriptomics
signature, which was significantly associated with worse prognosis in this cohort. B to D, in BCa cohorts of integrated 6-gene
signature consisting of CHIT1, DNMT1, GPD1, PLA2G4A, TARSL2 and SETD7, which was significantly associated with worse
prognosis in all 3 cohorts. B, TCGA. C, Kim et al (GSE13507).8 D, Lindgren et al (GSE32548).9
1918 INTEGRATIVE PATHWAY ANALYSIS OF METABOLIC SIGNATURE IN BLADDER CANCERpathway associated genes with the transcriptome
of large data sets provides an opportunity to
validate the prognostic value of gene signatures.
TCGA data set is an excellent resource as it
has set high standards with regard to sample
collection, sequencing technology and platform
analysis.
When applying the 30 metabolic gene signature
to TCGA cohort, we were able to observe a
significant difference in survival in patients with
an enrichment of metabolic genes compared to
those without such enrichment. This suggests that
up-regulation of these genes may be associated with
tumor progression and the pathway alterations from
our analysis may be of clinical relevance.
Specifically using the MSigDB platform we
determined significant enrichment for multiple
metabolic pathways and processes, namely argi-
nine and proline metabolism (p ¼ 4  10e11,q ¼ 6.93  10e12), tryptophan metabolism (p ¼
1.72  10e13, q ¼ 1.45  10e10), lysine degrada-
tion (p ¼ 3.15  10e13, q ¼ 1.77  10e10), b
alanine metabolism (p ¼ 2.18  10e12, q ¼ 9.19 
10e10) and glycerophospholipid metabolism (p ¼
1.6  10e9, q ¼ 5.38  10e7). Notably ALDH7A1,
ALDH2 and ALDH1B1 are present in the top 4
enriched pathways. Genes in the aldehyde dehy-
drogenase family have been previously reported as
associated with shorter survival in BCa.20 High
expression of GAMT (guanidinoacetate N-methyl-
transferase), which is present in the arginine and
proline metabolism pathway, has been associated
with better prognosis of BCa. Expression of TDO2
(tryptophan 2,3-dioxygenase) has been reported as
a potential target in immunotherapy of multiple
cancers, including BCa.21 Lastly the increase
in glycerophospholipids was observed in canine
models of BCa.22
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ture and observed significant enrichment for glyc-
erophospholipid metabolism (p ¼ 4.14ee5, q ¼
2.64ee2) and for glycerophospholipid biosynthesis
(p ¼ 4.7  10e5, q ¼ 2.64  10e2). They were driven
by genes such as PLA2G4A (phospholipase A2,
group IVA) and GPD1 (glycerol-3-phosphate dehy-
drogenase 1). As corroborated in prior studies in
animal models of BCa this result points to the
potential importance of modulating glycero-
phospholipids as a BCa therapeutic modality.
Our study has important limitations. Our anal-
ysis was performed on a single platform with a
limited number of patients. A metabolite derived
gene expression signature should ideally bevalidated in the same data set using gene expres-
sion data as well as in independent data sets with
long-term clinical followup data.CONCLUSIONS
Targeted mass spectrometry of BCa is highly sen-
sitive for detecting metabolic alterations. Pathway
analysis allows for the integration of metabolomic
and transcriptomic profiling to enhance data set size
and applicability to biological processes. We have
defined an integrated metabolic/transcriptomic
pathway signature associated with BCa progression
and report its potential value to predict the clinical
outcome.REFERENCES1. Cancer Facts and Figures 2014. Atlanta: Amer-
ican Cancer Society 2014.
2. Stein JP, Lieskovsky G, Cote R et al: Radical
cystectomy in the treatment of invasive bladder
cancer: long-term results in 1,054 patients.
J Clin Oncol 2001; 19: 666.
3. Xylinas E, Klute LA, Lotan Y et al: Blood- and
tissue-based biomarkers for prediction of out-
comes in urothelial carcinoma of the bladder.
Urol Oncol 2014; 32: 230.
4. Kiriluk KJ, Prasad SM, Patel AR et al: Bladder
cancer risk from occupational and environmental
exposures. Urol Oncol 2012; 30: 199.
5. Putluri N, Shojaie A, Vasu VT et al: Metabolomic
profiling reveals a role for androgen in activating
amino acid metabolism and methylation in
prostate cancer cells. PLoS One 2011; 6: e21417.
6. Cancer Genome Atlas Research Network:
Comprehensive molecular characterization of
urothelial bladder carcinoma. Nature 2014;
507: 315.
7. He B, Lanz RB, Fiskus W et al: GATA2 facilitates
steroid receptor coactivator recruitment to the
androgen receptor complex. Proc Natl Acad Sci
U S A 2014; 111: 18261.
8. Kim WJ, Kim EJ, Kim SK et al: Predictive value
of progression-related gene classifier in primary
non-muscle invasive bladder cancer. Mol Cancer
2010; 9: 3.
9. Lindgren D, Sj€odahl G, Lauss M et al: Integrated
genomic and gene expression profiling identifiestwo major genomic circuits in urothelial carci-
noma. PLoS One 2012; 7: e38863.
10. Budczies J, Klauschen F, Sinn BV et al: Cutoff
Finder: a comprehensive and straightforward
Web application enabling rapid biomarker cutoff
optimization. PLoS One 2012; 7: e51862.
11. Putluri N, Maity S, Creighton CJ et al: Pathway-
centric integrative analysis identifies RRM2 as a
prognostic marker in breast cancer associated
with poor survival and tamoxifen resistance.
Neoplasia 2014; 16: 390.
12. Meierhofer D, Weidner C and Sauer S: Correc-
tion to “integrative analysis of transcriptomics,
proteomics, and metabolomics data of white
adipose and liver tissue of high-fat diet and
rosiglitazone-treated insulin-resistant mice
identified pathway alterations and molecular
hubs.” J Proteome Res 2015; 14: 1643.
13. Meierhofer D, Weidner C and Sauer S: Integra-
tive analysis of transcriptomics, proteomics, and
metabolomics data of white adipose and liver
tissue of high-fat diet and rosiglitazone-treated
insulin-resistant mice identified pathway alter-
ations and molecular hubs. J Proteome Res
2014; 13: 5592.
14. Brink-Jensen K, Bak S, Jørgensen K et al: Inte-
grative analysis of metabolomics and tran-
scriptomics data: a unified model framework to
identify underlying system pathways. PLoS One
2013; 8: e72116.
15. Stanberry L, Mias GI, Haynes W et al: Integrative
analysis of longitudinal metabolomics data froma personal multi-omics profile. Metabolites
2013; 3: 741.
16. Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: the
metabolic requirements of cell proliferation.
Science 2009; 324: 1029.
17. Putluri N, Shojaie A, Vasu VT et al: Metabolomic
profiling reveals potential markers and bio-
processes altered in bladder cancer progression.
Cancer Res 2011; 71: 7376.
18. Dolfi SC, Chan LL, Qiu J et al: The metabolic
demands of cancer cells are coupled to their size
and protein synthesis rates. Cancer Metab 2013;
1: 20.
19. Duvel K, Yecies JL, Menon S et al: Activation
of a metabolic gene regulatory network
downstream of mTOR complex 1. Mol Cell
2010; 39: 171.
20. Su Y, Qiu Q, Zhang X et al: Aldehyde dehydro-
genase 1 A1-positive cell population is enriched
in tumor-initiating cells and associated with
progression of bladder cancer. Cancer Epidemiol
Biomarkers Prev 2010; 19: 327.
21. Pilotte L, Larrieu P, Stroobant V et al: Reversal of
tumoral immune resistance by inhibition of
tryptophan 2,3-dioxygenase. Proc Natl Acad Sci
U S A 2012; 109: 2497.
22. Dill AL, Ifa DR, Manicke NE et al: Lipid profiles of
canine invasive transitional cell carcinoma of the
urinary bladder and adjacent normal tissue by
desorption electrospray ionization imaging mass
spectrometry. Anal Chem 2009; 81: 8758.
